Glaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Buy GSK Shares
Add GSK to Watchlist
Add GSK to Alert

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 1,733.50

Bid: 1,732.50

Ask: 1,733.00

Change: 0.00 (0.00%)

Spread: 0.50 (0.029%)

Open: 0.00

High: 0.00

Low: 0.00

Prev. Close: 1,733.50

Last checked at -

Director/PDMR Shareholding

14 Oct 2021 16:31

RNS Number : 1470P

GlaxoSmithKline PLC

14 October 2021

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	956
			£14.0080	769
			£14.0080	640

d)	Aggregated information	2,365
d)	Aggregated volume Price	£14.0080
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr I Mackay
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	519
			£14.0080	443

d)	Aggregated information	962
	Aggregated volume Price	£14.0080
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr H Barron
b)	Position/status	Chief Scientific Officer and President, R&D
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$38.6600	557
			$38.6600	437
			$38.6600	331

d)	Aggregated information	1,325
d)	Aggregated volume Price	$38.6600
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Connor
b)	Position/status	President, Vaccines & Global Health
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	250
			£14.0080	242
			£14.0080	140

d)	Aggregated information	632
d)	Aggregated volume Price	£14.0080
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Conrad
b)	Position/status	SVP Human Resources
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	100
			£14.0080	92

d)	Aggregated information	192
	Aggregated volume Price	£14.0080
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr J Ford
b)	Position/status	Senior Vice President and General Counsel
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	142
			£14.0080	111

d)	Aggregated information	253
	Aggregated volume Price	£14.0080
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr J Ford
b)	Position/status	Senior Vice President and General Counsel
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$38.6600	47

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms S Jackson
b)	Position/status	SVP, Global Communications & CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	60
			£14.0080	56

d)	Aggregated information	116
	Aggregated volume Price	£14.0080
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr B McNamara
b)	Position/status	CEO, GSK Consumer Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$38.6600	93
			$38.6600	80
			$38.6600	101


d)	Aggregated information	274
d)	Aggregated volume Price	$38.6600
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	266
			£14.0080	232
			£14.0080	173

d)	Aggregated information	671
d)	Aggregated volume Price	£14.0080
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	237
			£14.0080	170
			£14.0080	136

d)	Aggregated information	543
d)	Aggregated volume Price	£14.0080
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Simard
b)	Position/status	President, Pharmaceuticals Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	85
			£14.0080	120
			£14.0080	102

d)	Aggregated information	307
d)	Aggregated volume Price	£14.0080
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms K Terrell
b)	Position/status	Chief Digital & Technology Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$38.6600	118
			$38.6600	81
			$38.6600	63

d)	Aggregated information	262
d)	Aggregated volume Price	$38.6600
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	138
			£14.0080	98
			£14.0080	79

d)	Aggregated information	315
d)	Aggregated volume Price	£14.0080
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Waterhouse
b)	Position/status	Chief Executive Officer of ViiV Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0080	163

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2021-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEZLFFFBLXFBB

Date		Source	Headline
3rd May 2024	3:30 pm	RNS	Director/PDMR Shareholding
1st May 2024	3:00 pm	RNS	Total Voting Rights
1st May 2024	7:00 am	RNS	1st Quarter Results
24th Apr 2024	7:00 am	RNS	US FDA accepts new indication filing for Jemperli
19th Apr 2024	3:30 pm	RNS	Director/PDMR Shareholding
17th Apr 2024	3:30 pm	RNS	Director/PDMR Shareholding
17th Apr 2024	7:05 am	RNS	GSK announces additional EAGLE-1 results
17th Apr 2024	7:00 am	RNS	Results from long-term data relating to Shingrix
16th Apr 2024	2:11 pm	RNS	Amendment - Director/PDMR Shareholding
16th Apr 2024	7:00 am	RNS	FDA accepts GSK meningitis vaccine candidate file
15th Apr 2024	3:30 pm	RNS	Director/PDMR Shareholding
4th Apr 2024	12:05 pm	RNS	Replacement - Total Voting Rights
2nd Apr 2024	3:00 pm	RNS	Total Voting Rights
26th Mar 2024	3:30 pm	RNS	Director/PDMR Shareholding
25th Mar 2024	1:00 pm	RNS	Notice of AGM
22nd Mar 2024	4:20 pm	RNS	Transfer of Treasury Shares
22nd Mar 2024	3:36 pm	RNS	Director/PDMR Shareholding
18th Mar 2024	9:30 am	RNS	New Phase III Jemperli data in endometrial cancer
13th Mar 2024	3:48 pm	RNS	Director/PDMR Shareholding
8th Mar 2024	5:12 pm	RNS	Board Committee Change
7th Mar 2024	7:00 am	RNS	GSK announces positive Blenrep DREAMM-8 results
6th Mar 2024	4:00 pm	RNS	ViiV LAI vs oral SOC data in adherence-challenged
5th Mar 2024	5:24 pm	RNS	GSK Annual Report 2023 on Form 20-F
5th Mar 2024	7:00 am	RNS	New ViiV LA formulation potential 4-month dosing
1st Mar 2024	3:00 pm	RNS	Total Voting Rights
1st Mar 2024	12:15 pm	RNS	GSK publishes Annual Report 2023
29th Feb 2024	7:05 am	RNS	Directorate Change
29th Feb 2024	7:00 am	RNS	Statement: Zantac (ranitidine) litigation
26th Feb 2024	3:30 pm	RNS	Director/PDMR Shareholding
26th Feb 2024	7:00 am	RNS	GSK announces positive EAGLE-1 headline results
22nd Feb 2024	3:30 pm	RNS	Director/PDMR Shareholding
21st Feb 2024	7:00 am	RNS	ViiV LAI superior to orals in adherence-challenged
20th Feb 2024	9:01 am	RNS	Julie Brown - External Appointment
19th Feb 2024	3:30 pm	RNS	Director/PDMR Shareholding
15th Feb 2024	3:32 pm	RNS	Director/PDMR Shareholding
15th Feb 2024	7:00 am	RNS	GSK completes acquisition of Aiolos Bio
13th Feb 2024	4:45 pm	RNS	Director/PDMR Shareholding - Replacement
13th Feb 2024	3:40 pm	RNS	Director/PDMR Shareholding
13th Feb 2024	3:35 pm	RNS	Director/PDMR Shareholding
13th Feb 2024	3:30 pm	RNS	Director/PDMR Shareholding
6th Feb 2024	7:10 am	RNS	FDA accepts Arexvy filing for adults 50-59 at risk
6th Feb 2024	7:05 am	RNS	Shingrix 18+ at risk China filing review accepted
6th Feb 2024	7:00 am	RNS	GSK presents positive DREAMM-7 phase III data
1st Feb 2024	3:30 pm	RNS	Director/PDMR Shareholding
1st Feb 2024	3:00 pm	RNS	Total Voting Rights
1st Feb 2024	7:00 am	RNS	Statement: Zantac (ranitidine) litigation
31st Jan 2024	7:00 am	RNS	Final Results
29th Jan 2024	7:05 am	RNS	EMA accepts Arexvy filing for adults 50-59 at risk
29th Jan 2024	7:00 am	RNS	European Commission authorises Omjjara in the EU
19th Jan 2024	3:30 pm	RNS	Director/PDMR Shareholding

Latest Share Chat

Glaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

Login to your account

Quickpicks are a member only feature

Login to your account